VITILIGO

This study is a 52 week long clinical trial (with potential to last 26 months if you qualify for additional extension) to test Povorcitinib in participants with VITILIGO. There are about 21 office visits over the entire 26 month duration.  There is compensation for your participation if you qualify and take part in this trial.  $100.00 per study visit.

To Qualify, you must meet the following INCLUSION CRITERIA:

1.)  MUST have a clinical diagnosis / history of VITILIGO.

2.)  MUST be 18+ years of age.

3.)  MUST have 5% or more Body Surface Area with VITILIGO (determined at screening visit)

To Qualify, you must NOT meet the following EXCLUSION CRITERIA:

1.)  MUST NOT be Pregnant or Breastfeeding

2.)  MUST NOT have Segmental VITILIGO (if you are unsure, please contact Research Staff).

3.)  MUST NOT have failed a JAK Inhibitor treatment previously.

 ClinicalTrials.gov Identifier:      NCT06113445 

https://clinicaltrials.gov/study/NCT06113445?term=povorcitinib&rank=5#locations